Recent progress in microneme-based vaccines development against Toxoplasma gondii.
- Author:
Masoud FOROUTAN
1
;
Leila ZAKI
;
Fatemeh GHAFFARIFAR
Author Information
- Publication Type:Review
- Keywords: Toxoplasma gondii; Vaccines; Microneme; Immune responses; Adjuvant
- MeSH: Animals; Humans; Mammals; Mice; Parasites; Seroepidemiologic Studies; Toxoplasma*; Toxoplasmosis; Vaccines*; Vaccines, DNA; Zoonoses
- From:Clinical and Experimental Vaccine Research 2018;7(2):93-103
- CountryRepublic of Korea
- Language:English
- Abstract: Toxoplasmosis is a cosmopolitan zoonotic disease, which infect several warm-blooded mammals. More than one-third of the human population are seropositive worldwide. Due to the high seroprevalence of Toxoplasma gondii infection worldwide, the resulting clinical, mental, and economical complications, as well as incapability of current drugs in the elimination of parasites within tissue cysts, the development of a vaccine against T. gondii would be critical. In the past decades, valuable advances have been achieved in order to identification of vaccine candidates against T. gondii infection. Microneme proteins (MICs) secreted by the micronemes play a critical role in the initial stages of host cell invasion by parasites. In this review, we have summarized the recent progress for MIC-based vaccines development, such as DNA vaccines, recombinant protein vaccines, vaccines based on live-attenuated vectors, and prime-boost strategy in different mouse models. In conclusion, the use of live-attenuated vectors as vehicles to deliver and express the target gene and prime-boost regimens showed excellent outcomes in the development of vaccines against toxoplasmosis, which need more attention in the future studies.
